The Clinical Uses Of Levodopa
DOWNLOAD
Download The Clinical Uses Of Levodopa PDF/ePub or read online books in Mobi eBooks. Click Download or Read Online button to get The Clinical Uses Of Levodopa book now. This website allows unlimited access to, at the time of writing, more than 1.5 million titles, including hundreds of thousands of titles in various foreign languages. If the content not found or just blank you must refresh this page
The Clinical Uses Of Levodopa
DOWNLOAD
Author : Gerald Stern
language : en
Publisher:
Release Date : 1975
The Clinical Uses Of Levodopa written by Gerald Stern and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 1975 with Medical categories.
The Clinical Uses Of Levodopa
DOWNLOAD
Author : Gerald Stern
language : en
Publisher: Springer London
Release Date : 1975-01-01
The Clinical Uses Of Levodopa written by Gerald Stern and has been published by Springer London this book supported file pdf, txt, epub, kindle and other format this book has been release on 1975-01-01 with Dopa categories.
Hepatotoxicity
DOWNLOAD
Author : Hyman J. Zimmerman
language : en
Publisher: Lippincott Williams & Wilkins
Release Date : 1999
Hepatotoxicity written by Hyman J. Zimmerman and has been published by Lippincott Williams & Wilkins this book supported file pdf, txt, epub, kindle and other format this book has been release on 1999 with Medical categories.
Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.
Drug Induced Liver Disease
DOWNLOAD
Author : Neil Kaplowitz
language : en
Publisher: CRC Press
Release Date : 2002-10-16
Drug Induced Liver Disease written by Neil Kaplowitz and has been published by CRC Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2002-10-16 with Medical categories.
Featuring more than 4100 references, Drug-Induced Liver Disease will be an invaluable reference for gastroenterologists, hepatologists, family physicians, internists, pathologists, pharmacists, pharmacologists, and clinical toxicologists, and graduate and medical school students in these disciplines.
Levodopa Pharmacokinetics From Stomach To Brain
DOWNLOAD
Author : Maria Nord
language : sv
Publisher: Linköping University Electronic Press
Release Date : 2019-01-07
Levodopa Pharmacokinetics From Stomach To Brain written by Maria Nord and has been published by Linköping University Electronic Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2019-01-07 with categories.
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders and it is caused by a loss of dopamine (DA) producing neurons in the basal ganglia in the brain. The PD patient suffers from motor symptoms such as tremor, bradykinesia and rigidity and treatment with levodopa (LD), the precursor of DA, has positive effects on these symptoms. Several factors affect the availability of orally given LD. Gastric emptying (GE) is one factor and it has been shown to be delayed in PD patients resulting in impaired levodopa uptake. Different enzymes metabolize LD on its way from the gut to the brain resulting in less LD available in the brain and more side effects from the metabolites. By adding dopa decarboxylase inhibitors (carbidopa or benserazide) or COMT-inhibitors (e.g. entacapone) the bioavailability of LD increases significantly and more LD can pass the blood-brain-barrier and be converted to DA in the brain. It has been considered of importance to avoid high levodopa peaks in the brain because this seems to induce changes in postsynaptic dopaminergic neurons causing disabling motor complications in PD patients. More continuously given LD, e.g. duodenal or intravenous (IV) infusions, has been shown to improve these motor complications. Deep brain stimulation of the subthalamic nucleus (STN DBS) has also been proven to improve motor complications and to make it possible to reduce the LD dosage in PD patients. In this doctoral thesis the main purpose is to study the pharmacokinetics of LD in patients with PD and motor complications; in blood and subcutaneous tissue and study the effect of GE and PD stage on LD uptake and the effect of continuously given LD (CDS) on LD uptake and GE; in blood and cerebrospinal fluid (CSF) when adding the peripheral enzyme inhibitors entacapone and carbidopa to LD infusion IV; in brain during STN DBSand during oral or IV LD treatment. To conclude, LD uptake is more favorable in PD patients with less severe disease and GE is delayed in PD patients. No obvious relation between LD uptake and GE or between GE and PD stage is seen and CDS decreases the LD levels. Entacapone increases the maximal concentration of LD in blood and CSF. This is more evident with additional carbidopa and important to consider in avoiding high LD peaks in brain during PD treatment. LD in brain increases during both oral and IV LD treatment and the DA levels follows LD well indicating that PD patients still have capacity to metabolize LD to DA despite probable pronounced nigral degeneration. STN DBS seems to increase putaminal DA levels and together with IV LD treatment also increases LD in brain possibly explaining why it is possible to decrease LD medication after STN DBS surgery. Parkinsons sjukdom (PS) är en av de vanligaste s.k. neurodegenerativasjukdomarna och orsakas av förlust av dopamin(DA)producerande nervceller i hjärnan. Detta orsakar motoriska symptom såsom skakningar, stelhet och förlångsammade rörelser. Levodopa (LD) är ett ämne, som kan omvandlas till DA i hjärnan och ge symptomlindring och det är oftast förstahandsval vid behandling av patienter med PS. Flera faktorer påverkar tillgängligheten av LD, bl.a. den hastighet som magsäcken tömmer sig med och denna verkar förlångsammad hos personer med PS vilket ger sämre tillgänglighet av LD i blodet och därmed i hjärnan. LD bryts även ner i hög grad av olika enzym ute i kroppen vilket leder till mindre mängd LD som hamnar i hjärnan och till fler nedbrytningsprodukter som orsakar biverkningar. Tillägg av enzymhämmare leder till ökad mängd LD som kan nå hjärnan och omvandlas till DA. Det anses viktigt att undvika höga toppar av LD i hjärnan då dessa verkar bidra till utvecklandet av besvärliga motoriska komplikationer hos patienter med PS. Om LD ges mer kontinuerligt, exempelvis som en kontinuerlig infusion in i tarmen eller i blodet, så minskar dessa motoriska komplikationer. Inopererande av stimulatorer i vissa delar av hjärnan (DBS) har också visat sig minska dessa motoriska komplikationer och även resultera i att man kan minska LD-dosen. Huvudsyftet med den här avhandlingen är att studera LD hos patienter med PS; i blod och fettvävnad då LD ges i tablettform och se om det finns något samband med LD-upptag och hastigheten på magsäckstömningen (MT) och om kontinuerligt given LD påverkar LD-upptaget eller MT; i blod och i ryggmärgsvätska då enzymhämmarna entakapon och karbidopa tillsätts LD; i hjärna vid behandling med DBS och då LD ges både som tablett och som infusion i blodet. Sammanfattningsvis kan vi se att LD-upptaget är mer gynnsamt hos patienter med PS i tidigare skede av sjukdomens komplikationsfas. MT är förlångsammad hos patienter med PS och det är inget tydligt samband mellan LD-upptag och MT eller mellan MT och sjukdomsgrad. Kontinuerligt given LD minskar LDnivåerna. Enzymhämmaren entakapon ökar den maximala koncentrationen av LD i blod och ryggmärgsvätska och effekten är mer tydlig vid tillägg av karbidopa vilket är viktigt att ta i beaktande vid behandling av PS för att undvika höga toppar av LD i hjärnan. LD ökar i hjärnan då man behandlar med LD i tablettform och som infusion i blodet och DA-nivåerna i hjärnan följer LD väl vilket visar på att patienter med PS fortfarande kan omvandla LD till DA trots trolig uttalad brist av de DA-producerande nervcellerna i hjärnan. DBS verkar öka DA i vissa områden i hjärnan och tillsammans med LD-infusion i blodet verkar det även öka LD i hjärnan och det kan förklara varför man kan sänka LDdosen efter DBS-operation.
Oxidative Stress And Neurodegenerative Disorders
DOWNLOAD
Author : G. Ali Qureshi
language : en
Publisher: Elsevier
Release Date : 2007-03-22
Oxidative Stress And Neurodegenerative Disorders written by G. Ali Qureshi and has been published by Elsevier this book supported file pdf, txt, epub, kindle and other format this book has been release on 2007-03-22 with Science categories.
Oxidative stress is the result of an imbalance in pro-oxidant/antioxidant homeostasis that leads to the generation of toxic reactive oxygen species. Brain cells are continuously exposed to reactive oxygen species generated by oxidative metabolism, and in certain pathological conditions defense mechanisms against oxygen radicals may be weakened and/or overwhelmed. DNA is a potential target for oxidative damage, and genomic damage can contribute to neuropathogenesis. It is important therefore to identify tools for the quantitative analysis of DNA damage in models on neurological disorders. This book presents detailed information on various neurodegenerative disorders and their connection with oxidative stress. This information will provide clinicians with directions to treat these disorders with appropriate therapy and is also of vital importance for the drug industries for the design of new drugs for treatment of degenerative disorders. * Contains the latest information on the subject of neurodegenerative disorders* Reflects on various factors involved in degeneration and gives suggestions for how to tackle these problems
Neuropsychopharmacotherapy
DOWNLOAD
Author : Peter Riederer
language : en
Publisher: Springer Nature
Release Date : 2022-11-04
Neuropsychopharmacotherapy written by Peter Riederer and has been published by Springer Nature this book supported file pdf, txt, epub, kindle and other format this book has been release on 2022-11-04 with Medical categories.
This book provides a reference guide describing the current status of medication in all major psychiatric and neurological indications, together with comparisons of pharmacological treatment strategies in clinical settings in Europe, USA, Japan and China. In addition, it highlights herbal medicine as used in China and Japan, as well as complementary medicine and nutritional aspects. This novel approach offers international readers a global approach in a single dedicated publication and is also a valuable resource for anyone interested in comparing treatments for psychiatric disorders in three different cultural areas. There are three volumes devoted to Basic Principles and General Aspects, offering a general overview of psychopharmacotherapy (Vol. 1); Classes, Drugs and Special Aspects covering the role of psychotropic drugs in the field of psychiatry and neurology (Vol. 2) and Applied Psychopharmacotherapy focusing on applied psychopharmacotherapy (Vol. 3). These books are invaluable to psychiatrists, neurologists, neuroscientists, medical practitioners and clinical psychologists.
A Study Of The Potential Clinical Application Of Levodopa L Dopa Entrapped Within Liposomes In The Treatment Of Parkinson S Disease
DOWNLOAD
Author :
language : en
Publisher:
Release Date : 1993
A Study Of The Potential Clinical Application Of Levodopa L Dopa Entrapped Within Liposomes In The Treatment Of Parkinson S Disease written by and has been published by this book supported file pdf, txt, epub, kindle and other format this book has been release on 1993 with categories.
Mucuna Versus Parkinson Treatment With Natural Levodopa
DOWNLOAD
Author : Rafael González Maldonado
language : en
Publisher: Rafael González Maldonado
Release Date : 2014-08-19
Mucuna Versus Parkinson Treatment With Natural Levodopa written by Rafael González Maldonado and has been published by Rafael González Maldonado this book supported file pdf, txt, epub, kindle and other format this book has been release on 2014-08-19 with Medical categories.
“Mucuna pruriens” is a bean that grows in the tropics. It is very rich in natural levodopa that is better tolerated and more potent than the synthetic levodopa in Sinemet or Stalevo. Two prestigious neurologists have patented extracts of mucuna seeds as a treatment for Parkinson's. Meanwhile, patients have recorded their positive experiences with mucuna; they buy it online (no prescription needed) and use it in secrecy without consulting their neurologist. Neither the patients nor the doctors (most of them) have clear ideas about this plant, its ingredients (not only levodopa), the proportions in which it is absorbed, or how to manage it. "Mucuna versus Parkinson: Natural Levodopa Treatment" is so far the most complete and up-to-date monograph on the subject, it describes the theoretical and practical approaches to the use of this plant as a treatment option for Parkinson's disease. Also included are more than one hundred of references.
Parkinson S Disease Current And Future Therapeutics And Clinical Trials
DOWNLOAD
Author : Néstor Gálvez-Jiménez
language : en
Publisher: Cambridge University Press
Release Date : 2016-03-24
Parkinson S Disease Current And Future Therapeutics And Clinical Trials written by Néstor Gálvez-Jiménez and has been published by Cambridge University Press this book supported file pdf, txt, epub, kindle and other format this book has been release on 2016-03-24 with Medical categories.
This book emphasizes treatment options for Parkinson's disease, providing the necessary clinical and scientific basis for the foundations of solid therapeutics.
